Adeno-associated virus-mediated expression of acid sphingomyelinase decreases atherosclerotic lesion formation in apolipoprotein E-/- mice

Journal of Gene Medicine

Volumn 13, Issue 6, 2011, Pages 324-332

  Leger, Andrew J ^a   Mosquea, Leocadia M ^a   Li, Lingyun ^a   Chuang, Weilien ^a   Pacheco, Joshua ^a   Taylor, Kristin ^a   Luo, Zhengyu ^a   Piepenhagen, Peter ^a   Ziegler, Robin ^a   Moreland, Rod ^a   Urabe, Akihiro ^a   Jiang, Canwen ^a   Cheng, Seng H ^a   Yew, Nelson S ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Adeno associated virus; Apolipoprotein E knockout mice; Atherosclerosis; Lesions; Lipoprotein aggregation; Sphingomyelinase

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; VERY LOW DENSITY LIPOPROTEIN;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA SINUS; ARTERY LESION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE THERAPY; HYPERLIPOPROTEINEMIA TYPE 3; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS RECOMBINANT;

ANALYSIS OF VARIANCE; ANIMALS; AORTA; APOLIPOPROTEINS E; DEPENDOVIRUS; HISTOLOGICAL TECHNIQUES; HUMANS; LIPOPROTEINS; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; SPHINGOMYELIN PHOSPHODIESTERASE;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 79959708514     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1575     Document Type: Article

References (30)

1. Jenkins RW, Canals D, Hannun YA. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal 2009; 21: 836-846.
2. Pavoine C, Pecker F. Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc Res 2009; 82: 175-183.
3. Schissel SL, Keesler GA, Schuchman EH, et al. The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. J Biol Chem 1998; 273: 18250-18259.
4. Marathe S, Schissel SL, Yellin MJ, et al. Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J Biol Chem 1998; 273: 4081-4088.
5. Wong ML, Xie B, Beatini N, et al. Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci USA 2000; 97: 8681-8686.
6. Schissel SL, Tweedie-Hardman J, Rapp JH, et al. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996; 98: 1455-1464.
7. Schissel SL, Jiang X, Tweedie-Hardman J, et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J Biol Chem 1998; 273: 2738-2746.
8. Oorni K, Posio P, Ala-Korpela M, et al. Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. Arterioscler Thromb Vasc Biol 2005; 25: 1678-1683.
9. Devlin CM, Leventhal AR, Kuriakose G, et al. Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler Thromb Vasc Biol 2008; 28: 1723-1730.
10. Leventhal AR, Chen W, Tall AR, et al. Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. J Biol Chem 2001; 276: 44976-44983.
11. Devlin C, Leventhal AR, Kuriakose G, et al. In vivo evidence that secretory sphingomyelinase is proatherogenic while lysosomal sphingomyelinase is antiatherogenic. Circulation 2004; 110 (Suppl 17): III1-III835.
12. Barbon CM, Ziegler RJ, Li C, et al. AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease. Mol Ther 2005; 12: 431-440.
13. Miranda SR, He X, Simonaro CM, et al. Infusion of recombinant human acid sphingomyelinase into niemann-pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J 2000; 14: 1988-95.
14. Mingozzi F, Liu YL, Dobrzynski E, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003; 111: 1347-1356.
15. O'Riordan CR, Lachapelle AL, Vincent KA, et al. Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV). J Gene Med 2000; 2: 444-454.
16. Bielawski J, Szulc ZM, Hannun YA, et al. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 2006; 39: 82-91.
17. Merrill AH, Jr., Sullards MC, Allegood JC, et al. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 2005; 36: 207-224.
18. Zhao H, Przybylska M, Wu IH, et al. Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology 2009; 50: 85-93.
19. Brousseau T, Clavey V, Bard JM, et al. Sequential ultracentrifugation micromethod for separation of serum lipoproteins and assays of lipids, apolipoproteins, and lipoprotein particles. Clin Chem 1993; 39: 960-964.
20. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-561.
21. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007; 116: 1832-1844.
22. Bhuvaneswaran C, Venkatesan S, Mitropoulos KA. Lysosomal accumulation of cholesterol and sphingomyelin: evidence for inhibition of acid sphingomyelinase. Eur J Cell Biol 1985; 37: 98-106.
23. Jiang XC, Paultre F, Pearson TA, et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 20: 2614-2618.
24. Shimada M, Ishibashi S, Inaba T, et al. Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc Natl Acad Sci USA 1996; 93: 7242-7246.
25. Yagyu H, Ishibashi S, Chen Z, et al. Overexpressed lipoprotein lipase protects against atherosclerosis in apolipoprotein E knockout mice. J Lipid Res 1999; 40: 1677-1685.
26. Clee SM, Bissada N, Miao F, et al. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J Lipid Res 2000; 41: 521-531.
27. Tabas I, Li Y, Brocia RW, et al. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein (a) retention and macrophage foam cell formation. J Biol Chem 1993; 268: 20419-20432.
28. Hakala JK, Oorni K, Pentikainen MO, et al. Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol 2001; 21: 1053-1058.
29. Jonsson-Rylander AC, Lundin S, Rosengren B, et al. Role of secretory phospholipases in atherogenesis. Curr Atheroscler Rep 2008; 10: 252-259.
30. Maor I, Aviram M. Macrophage released proteoglycans are involved in cell-mediated aggregation of LDL. Atherosclerosis 1999; 142: 57-66.